In the previous article, we discussed how hippocampal atrophy progresses across different stages of Alzheimer’s disease and how MRI reveals these changes over time. However, hippocampal volume loss is not limited to Alzheimer’s disease. Similar structural changes are reported across several neurodegenerative disorders, although the patterns and rates of atrophy differ.
Hippocampal atrophy is one of the most consistently measurable structural findings on brain MRI. Rather than pointing to a single diagnosis, it reflects long-standing neurodegenerative processes affecting memory-related networks. This makes hippocampal atrophy an important cross-condition neuroimaging biomarker, particularly when interpreted in the context of disease progression and longitudinal MRI assessment.
In neuroimaging, a biomarker is not a diagnosis. Instead, it is an objectively measurable feature that reflects an underlying biological process. In the context of neurodegenerative disorders, biomarkers help researchers and clinicians describe how the brain changes over time, even when symptoms overlap between conditions.
Neuroimaging biomarkers are generally divided into two categories:
Structural MRI biomarkers are widely used in neurodegenerative disorders because they capture changes that accumulate slowly and persist over time. Unlike functional measures, which may fluctuate due to attention, medication, or temporary physiological states, structural changes represent tissue that has been permanently affected.
For this reason, MRI-based structural biomarkers, particularly hippocampal atrophy, have become central to both research studies and longitudinal observational frameworks.
The hippocampus is situated within the medial temporal lobe, and it plays a critical role in memory formation, consolidation, and spatial navigation functions, which are commonly disrupted across many neurodegenerative disorders. However, the hippocampus dysfunction occurs due to
These explain why hippocampal atrophy often appears early in the disease course of several neurodegenerative disorders, even when other brain regions still appear relatively preserved.
Importantly, hippocampal atrophy MRI assessment relies on volumetric quantification, rather than qualitative signal changes. Volume loss provides a cumulative measure of degeneration, making it more stable and reproducible across time points and imaging centers. This reliability is a key reason the hippocampus has been studied so extensively in neurodegenerative imaging research.
One of the most important conclusions from decades of neuroimaging research is that hippocampal atrophy is not disease-specific. Overlapping patterns are common across neurodegenerative disorders.
Meaningful distinctions emerge when examining:
Without this contextual interpretation, hippocampal atrophy MRI findings risk being oversimplified. In practice, they are most informative when combined with broader structural patterns and longitudinal data.
MRI remains the preferred modality for evaluating hippocampal atrophy due to its excellent soft-tissue contrast and spatial resolution. Most volumetric analyses rely on high-resolution T1-weighted sequences acquired using standardized protocols.
Both cross-sectional and longitudinal assessments are used in neurodegenerative disorders research. While cross-sectional measurements provide a snapshot, longitudinal MRI allows direct observation of change over time, which is particularly valuable for tracking disease progression.
Volumetric measurement is consistently favored over visual rating because it offers objective, reproducible data and reduces observer-dependent variability.
Maintaining scientific rigor requires acknowledging limitations:
These limitations reinforce the need for standardization and contextual interpretation when using hippocampal atrophy MRI as a biomarker in neurodegenerative disorders.
Quantitative MRI analysis has improved the consistency of hippocampal atrophy assessment by reducing reliance on subjective visual interpretation. Automated hippocampal segmentation enables objective volumetric measurement, allowing structural changes to be evaluated against age- and population-based reference datasets. This reference-based comparison is particularly important in neurodegenerative disorders, where normal aging and disease-related changes often overlap.
AI-assisted tools also support longitudinal change tracking, making it possible to measure subtle volume loss over time with reduced inter-reader variability. Within this context, Alzevita is a decision-support system designed to support consistency and confidence in structural assessment. It assists radiological and clinical interpretation by providing quantitative insights and Longitudinal analysis.
Hippocampal atrophy biomarkers are widely applied across:
Across these settings, the emphasis remains on understanding structural progression, not assigning disease labels.
Hippocampal atrophy is a consistently observed structural finding across neurodegenerative disorders, providing insight into progressive changes affecting memory-related brain networks rather than serving as a disease-specific marker. When evaluated using hippocampal atrophy MRI, differences in atrophy patterns, regional involvement, and longitudinal progression offer meaningful structural context, especially when combined with quantitative volumetric analysis. Advances in automated and AI-assisted measurement now support more consistent and objective assessment, reinforcing the value of longitudinal MRI-based biomarkers while maintaining a clear distinction between decision-support tools and diagnostic conclusions.